TAP molecules are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected.
Denis Corin, CEO of TapImmune, said: “This is a tremendous milestone for the company. The notice of allowance for this patent gives our company a well-protected platform from which to continue our development on a number of potential products in both the prophylactic and therapeutic vaccine markets and will allow us to approach potential partners with confidence.”